```html

Cytomegalovirus (CMV) Infection: A Complete Patient‑Friendly Guide

Overview

Cytomegalovirus (CMV) is a common member of the herpesviridae family, the same family that causes herpes simplex and varicella‑zoster (chickenpox). Once a person contracts CMV, the virus remains in the body for life and can reactivate, especially when the immune system is weakened.

Who it affects: CMV can infect anyone—infants, children, adolescents, and adults. Most healthy individuals experience a mild, flu‑like illness or no symptoms at all. However, certain groups are at higher risk for severe disease:

• Pregnant women (risk of congenital infection)
• Newborns and infants, especially pre‑term babies
• People with weakened immune systems – e.g., organ‑transplant recipients, HIV‑positive individuals, patients on chemotherapy or high‑dose steroids

Prevalence: Worldwide, CMV seroprevalence ranges from 40% to 100% depending on age, geography, and socioeconomic status. In the United States, about 50–70% of adults have been infected by age 40, and prevalence exceeds 90% in low‑income regions (WHO, 2022).

Symptoms

Most healthy people have no recognizable illness, but when symptoms do appear they can be nonspecific. Below is a comprehensive list, grouped by the population most commonly affected.

General (healthy adolescents & adults)

• Fever – low‑grade to high, often lasting 1–2 weeks.
• Fatigue – persistent tiredness that interferes with daily activities.
• Sore throat – may be accompanied by swollen tonsils.
• Swollen lymph nodes – especially behind the ears and in the neck.
• Headache – can be mild or throbbing.
• Myalgias (muscle aches) and arthralgias (joint pain).
• Hepatosplenomegaly – mild enlargement of the liver and spleen, sometimes noted on imaging.
• Rash – maculopapular or petechial, though uncommon.

Pregnant women

• Symptoms often mimic a mild viral illness: fever, fatigue, and lymphadenopathy.
• Some women develop hepatitis (elevated liver enzymes) or a transient rash.
• Importantly, many infections are asymptomatic, yet the virus can cross the placenta.

Newborns & infants (congenital CMV)

• Hearing loss – sensorineural, may be present at birth or develop later.
• Microcephaly – smaller head size due to impaired brain growth.
• Jaundice and hepatic dysfunction.
• Chorioretinitis – inflammation of the retina causing visual problems.
• Seizures or developmental delay.
• Low birth weight and prematurity.

Immunocompromised patients

• Retinitis – painless vision loss, characteristic in AIDS patients.
• Colitis or gastroenteritis – abdominal pain, watery or bloody diarrhea.
• Pneumonitis – cough, shortness of breath, hypoxia.
• Encephalitis – confusion, seizures, focal neurological deficits.
• Hepatitis – markedly elevated liver enzymes.
• Graft rejection in transplant recipients, often presenting with fever and organ dysfunction.

Causes and Risk Factors

CMV is transmitted through direct contact with infected body fluids, including:

• Saliva (kissing, sharing utensils)
• Urine (especially in childcare settings)
• Blood and blood products
• Breast milk
• Sexual contact
• Transplantation of solid organs or hematopoietic stem cells
• Vertical transmission from mother to fetus during pregnancy

Key risk factors

• Pregnancy – especially primary infection during the first trimester.
• Close contact with young children – daycare workers and parents have higher seroconversion rates.
• Immunosuppression – HIV infection (CD4 < 50 cells/µL), chemotherapy, biologic agents, high-dose steroids.
• Organ transplantation – especially if the donor was CMV‑positive.
• Blood transfusion – rare in countries that screen donors, but still a documented source.

Diagnosis

Because CMV symptoms overlap with many other viral illnesses, laboratory testing is essential.

Serology

• CMV IgM – indicates recent primary infection (positive for ~4–6 weeks).
• CMV IgG – denotes past exposure; used to establish immunity in transplant donors/recipients.

Polymerase Chain Reaction (PCR)

Quantitative PCR detects CMV DNA in blood, urine, cerebrospinal fluid (CSF), or tissue samples. It is the preferred method for:

• Monitoring viral load in immunocompromised patients.
• Diagnosing congenital infection (PCR on urine or saliva within 3 weeks of birth).
• Assessing organ involvement (e.g., CMV DNA in BAL fluid for pneumonitis).

Culture

Viral culture is less common due to slower turnaround but may be used for research or in settings lacking PCR.

Histopathology

Biopsy of affected tissue (e.g., colon, retina) can reveal characteristic “owl’s eye” nuclear inclusions on H&E staining.

Imaging

• Chest X‑ray or CT for pneumonitis.
• MRI of brain in encephalitis.
• Ophthalmologic examination (fundoscopy) for retinitis.

Treatment Options

Treatment decisions depend on the patient’s immune status, severity of disease, and organ involvement.

Antiviral Medications

• Ganciclovir (intravenous) – first‑line for severe disease (e.g., CMV pneumonia, retinitis). Dose: 5 mg/kg IV q12h.
• Valganciclovir (oral prodrug of ganciclovir) – used for mild‑to‑moderate disease and for long‑term suppressive therapy. Typical dose: 900 mg PO BID for 21 days in congenital infection.
• Foscarnet – reserved for ganciclovir‑resistant CMV or when myelosuppression is prohibitive. Requires careful renal monitoring.
• Cidofovir – third‑line agent, nephrotoxic; used only after failure of other agents.

Therapeutic drug monitoring (TDM) is recommended for ganciclovir/valganciclovir to maintain trough levels 1–2 µg/mL and reduce toxicity.

Adjunctive Therapies

• Intravenous immune globulin (IVIG) – sometimes added in severe congenital infection or in transplant patients with CMV disease.
• Reduction of immunosuppression – in transplant recipients, adjusting steroids or antimetabolites can help control viral replication.

Lifestyle & Supportive Care

• Hydration and fever control (acetaminophen, avoid NSAIDs if liver disease present).
• Rest and nutrition to support immune recovery.
• Regular ophthalmology follow‑up for patients with retinal involvement.

Living with Cytomegalovirus Infection

Even after acute illness, CMV remains in the body. The following strategies help patients stay healthy and minimize reactivation.

• Adhere to antiviral regimens as prescribed; never stop medication without discussing it with a provider.
• Monitor viral load regularly if you’re immunocompromised; most centers schedule PCR every 1–4 weeks during treatment.
• Vaccination – no CMV vaccine is available yet, but stay up‑to‑date on flu, pneumococcal, and COVID‑19 vaccines, which reduce overall illness burden.
• Hand hygiene – wash hands thoroughly after changing diapers, handling raw meat, or touching bodily fluids.
• Safe food practices – avoid unpasteurized dairy and undercooked meat, which can harbor CMV.
• Sexual health – use condoms, especially if you have a partner who is pregnant or immunocompromised.
• Pregnancy planning – women with known CMV IgG positivity should discuss timing and monitoring with obstetricians; avoid exposure to saliva of young children during pregnancy.
• Psychosocial support – join support groups for transplant recipients or families of children with congenital CMV; coping strategies improve quality of life.

Prevention

Because CMV spreads through everyday contact, primary prevention focuses on hygiene and risk‑reduction behaviors.

• Hand washing – 20 seconds with soap, especially after diaper changes, contact with urine, or before eating.
• Avoid sharing utensils, cups, or food with toddlers, who frequently shed CMV in saliva.
• Screen blood products – most high‑income countries test donors for CMV; request CMV‑negative or leukoreduced blood if you’re immunocompromised.
• Breastfeeding guidance – CMV can be transmitted via breast milk, but benefits usually outweigh risks. In premature infants, some NICUs use CMV‑screened milk or pasteurization.
• Safe sex practices – use condoms and limit number of sexual partners.
• Pre‑transplant evaluation – matching CMV‑negative donors with CMV‑negative recipients reduces post‑operative disease.
• Pregnancy counseling – seronegative pregnant women should be educated about avoiding saliva exposure from toddlers.

Complications

If left untreated or in high‑risk individuals, CMV can cause serious, sometimes irreversible damage.

• Congenital CMV – leads to sensorineural hearing loss (affects ~10–15% of infected infants), intellectual disability, cerebral palsy.
• Retinitis – common cause of blindness in AIDS patients; untreated disease can progress to retinal detachment.
• CMV colitis – chronic diarrhea, malabsorption, weight loss.
• Pneumonitis – can progress to respiratory failure requiring mechanical ventilation.
• Encephalitis – seizures, long‑term cognitive deficits.
• Graft loss – in transplant recipients, CMV disease is a leading cause of organ rejection and failure.
• Hemorrhagic cystitis – bladder inflammation causing painful bleeding, especially after bone‑marrow transplant.

When to Seek Emergency Care

References

• Mayo Clinic. Cytomegalovirus (CMV) infection. https://www.mayoclinic.org
• Centers for Disease Control and Prevention (CDC). CMV and Pregnancy. https://www.cdc.gov
• National Institutes of Health (NIH) – ClinicalTrials.gov. CMV treatment guidelines. https://clinicalinfo.org
• World Health Organization (WHO). Global prevalence of CMV infection. 2022 report.
• Cleveland Clinic. Cytomegalovirus (CMV) in Immunocompromised Patients. https://my.clevelandclinic.org
• American Society of Transplantation. CMV in solid‑organ transplantation. 2021 consensus statement.

```